HEM — Hemostemix Income Statement
0.000.00%
Last trade - 00:00- CA$14.10m
- CA$18.81m
Annual income statement for Hemostemix, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 4.7 | 7.55 | 6.66 | 4.58 | 1.96 |
| Operating Profit | -4.7 | -7.55 | -6.66 | -4.58 | -1.96 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -4.87 | -7.77 | -6.54 | -4.75 | -2.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -4.87 | -7.77 | -6.29 | -5.24 | -2.5 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -4.87 | -7.77 | -6.29 | -5.24 | -2.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4.87 | -7.77 | -6.29 | -5.24 | -2.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.324 | -0.238 | -0.109 | -0.075 | -0.033 |